ArticleOncology reports2025
CYP8B1 is a prognostic biomarker with important functional implications in hepatocellular carcinoma.
Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LRRC59 inhibits perk pathway‑induced apoptosis and promotes cell proliferation, migration and invasion in colorectal cancer cells.Oncology reports · 2026Article
- Long non-coding RNA in hepatocellular carcinoma: mechanistic insights and therapeutic perspectives.Cellular oncology (Dordrecht, Netherlands) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytochrome P450 8B1 (CYP8B1) is a critical enzyme in bile acid metabolism. Using multiple databases, including Gene Expression Omnibus, UALCAN (The University of Alabama at Birmingham Cancer data analysis Portal, GEPIA (Gene Expression Profiling Interactive Analysis), TCGA (The Cancer Genome Atlas) and GTEx (Genotype‑Tissue Expression), the present study analyzed CYP8B1 expression and its prognostic value in hepatocellular carcinoma (HCC). The results showed that CYP8B1 expression was significantly lower in HCC compared with normal tissues, and reduced CYP8B1 expression was associated with poor prognosis in patients with HCC. CYP8B1 was overexpressed in HCC cell lines (Huh7 and Hep3b cells); cell proliferation was assessed using Cell Counting Kit‑8 and EdU assays, while apoptosis was evaluated using the TUNEL assay. CYP8B1 overexpression inhibited proliferation and promoted apoptosis in HCC cells. Additionally, analyses via UALCAN and the Metascape platform showed that CYP8B1 expression was negatively associated with YWHAZ (Tyrosine 3/tryptophan 5 monooxygenase activation protein ζ), the regulation of PLK (Polo‑like kinase) activity during G2/M transition, and the intrinsic apoptosis pathway. Immunoblotting revealed that CYP8B1 overexpression decreased YWHAZ levels. Consistently, the expression of cyclin‑dependent kinase 1) and CCNB1 (Cyclin B1), key markers of G2/M transition, was also diminished following CYP8B1 overexpression. Furthermore, the pro‑apoptotic protein Bax was upregulated, while the anti‑apoptotic protein Bcl‑2 was downregulated. In conclusion, CYP8B1 holds promise as a potential prognostic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.